Radioiodinated tracers for myocardial imaging

Journal Article · Sun Apr 01 00:00:00 EST 1990 · Seminars in Nuclear Medicine; (USA)

DOI:https://doi.org/10.1016/S0001-2998(05)80165-5· OSTI ID:6870395

Kulkarni, P V; Corbett, J R ^[1]

---

1. Univ. of Texas Southwestern Medical Center, Dallas (USA)

Recent advances in the efficient production of high purity radioiodine (123I) and new efficient radiolabeling techniques have allowed the development of new classes of cardiovascular radiopharmaceuticals. These include 123I-labeled fatty acids to assess myocardial metabolism, 123I-metaiodobenzylguanidine (MIBG) for myocardial neuronal activity, labeled monoclonal antibodies for myocardial necrosis, and labeled lipoproteins for receptor concentration. 123I-labeled fatty acids and MIBG are under clinical investigation with encouraging results. 123I- and 111In-labeled fragments of monoclonal antibodies to myosin have been used for imaging myocardial necrosis in humans. The development of radiotracers for imaging of cholinergic and adrenergic receptors is still in the experimental stage. Recent advances in imaging instrumentation and radiopharmaceuticals have resulted in cardiac imaging applications beyond blood pool ventriculography, perfusion, and infarct-avid imaging. Developments of radioiodine (123I)-labeled agents promise to play an important role in the assessment of myocardial metabolism, neuronal activity, and receptor concentration. The chemistry of iodine is well defined compared with that of 99mTc; therefore, iodine isotopes are well suited for labeling biologically important molecules. Among the iodine isotopes, 123I has nearly ideal nuclear properties for nuclear medical applications with a 13.3-hour half-life (T1/2) and 159 keV gamma emission (83%). Despite the nearly ideal chemical and nuclear properties of 123I, the widespread application of 123I-based radiopharmaceuticals in clinical practice has been limited by high production costs (123I is produced in a cyclotron), relatively limited availability, and the presence of undesirable radionuclidic impurities (124I, T1/2 = 4.2 days; 125I, T1/2 = 60 days; 126I, T1/2 = 13.1 days). 77 references.

• OSTI ID: 6870395
• Journal Information: Seminars in Nuclear Medicine; (USA), Vol. 20:2; ISSN 0001-2998
• Country of Publication: United States
• Language: English

Related Subjects

62 RADIOLOGY AND NUCLEAR MEDICINE
MYOCARDIUM
IMAGE PROCESSING
RADIOPHARMACEUTICALS
CHEMICAL PREPARATION
IODINE 123
LABELLING
METABOLISM
MONOCLONAL ANTIBODIES
NUCLEAR MEDICINE
REVIEWS
ANTIBODIES
BETA DECAY RADIOISOTOPES
BODY
CARDIOVASCULAR SYSTEM
DOCUMENT TYPES
DRUGS
ELECTRON CAPTURE RADIOISOTOPES
HEART
HOURS LIVING RADIOISOTOPES
INTERMEDIATE MASS NUCLEI
IODINE ISOTOPES
ISOTOPES
LABELLED COMPOUNDS
MEDICINE
MUSCLES
NUCLEI
ODD-EVEN NUCLEI
ORGANS
PROCESSING
RADIOISOTOPES
SYNTHESIS
550601* - Medicine- Unsealed Radionuclides in Diagnostics